Medicare AdvantageCoverageMedium impact
MA08.110d, Luspatercept–aamt (Reblozyl®)
Independence Blue Cross·Hematology, Oncology·Pharmacy
Effective date
Jan 17, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.110d for Luspatercept-aamt (Reblozyl®) has been updated with changes to coverage criteria, medical necessity requirements, and coding guidelines. This affects billing for this specialty oncology/hematology medication used to treat anemia in certain blood disorders.
Action Required
By January 17, 2025: Billing team must review updated medical necessity criteria for Luspatercept-aamt (Reblozyl®) claims for Medicare Advantage patients. Providers treating blood disorders must ensure documentation meets new requirements before submitting claims. Update prior authorization processes if required by the new coverage position.